Ethyl 1-(2-phenylquinazolin-4-yl)piperidine-3-carboxylate | 1391611-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Ethyl 1-(2-phenylquinazolin-4-yl)piperidine-3-carboxylate
• 英文别名: ethyl 1-(2-phenylquinazolin-4-yl)piperidine-3-carboxylate
• CAS: 1391611-34-9
• 化学式: C₂₂H₂₃N₃O₂
• 分子量: 361.444
• InChiKey: MATIPRBVRDMSJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  55.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-苯基-4-[3H]喹唑啉酮 在 五氯化磷 、 potassium carbonate 、 三氯氧磷 作用下， 以 丙酮 为溶剂， 反应 5.0h， 生成 Ethyl 1-(2-phenylquinazolin-4-yl)piperidine-3-carboxylate
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents

  摘要：

  Twenty-two quinazoline derivatives have been synthesised and examined for their anti-tumour activity against three tumour cell lines, namely human breast cancer cell line (MCF-7), human cervical cancer cell line (HeLa) and human hepatoma cell line (HepG2). Twelve of the tested compounds have shown promising anti-tumour activity with an IC50 range of 5.0-9.7 mu g/mL. Regarding the spectrum of activity, five compounds exhibited interesting anti-proliferative properties against the three tested cell lines comparable to the reference drug (dasatinib).

  DOI：

  10.3109/14756366.2011.601302

文献信息

• Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents
  作者：Ahmed M. Alafeefy、Abdelkader E. Ashour

  DOI：10.3109/14756366.2011.601302

  日期：2012.8.1

  Twenty-two quinazoline derivatives have been synthesised and examined for their anti-tumour activity against three tumour cell lines, namely human breast cancer cell line (MCF-7), human cervical cancer cell line (HeLa) and human hepatoma cell line (HepG2). Twelve of the tested compounds have shown promising anti-tumour activity with an IC50 range of 5.0-9.7 mu g/mL. Regarding the spectrum of activity, five compounds exhibited interesting anti-proliferative properties against the three tested cell lines comparable to the reference drug (dasatinib).